End-of-day quote
Shanghai S.E.
23:00:00 25/06/2024 BST
|
5-day change
|
1st Jan Change
|
8.72
CNY
|
+3.32%
|
|
-2.02%
|
-23.10%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,546
|
1,513
|
1,398
|
1,588
|
1,883
|
2,097
|
Enterprise Value (EV)
1 |
1,380
|
1,230
|
1,047
|
1,407
|
1,622
|
1,857
|
P/E ratio
|
50.7
x
|
84.6
x
|
118
x
|
91.2
x
|
59.9
x
|
70.9
x
|
Yield
|
0.63%
|
0.37%
|
0.24%
|
0.33%
|
0.52%
|
0.43%
|
Capitalization / Revenue
|
1.76
x
|
1.74
x
|
1.83
x
|
2.37
x
|
2.11
x
|
2.27
x
|
EV / Revenue
|
1.57
x
|
1.41
x
|
1.37
x
|
2.1
x
|
1.81
x
|
2.01
x
|
EV / EBITDA
|
41.6
x
|
42.6
x
|
21.8
x
|
60.3
x
|
58.6
x
|
56.6
x
|
EV / FCF
|
69.2
x
|
62.1
x
|
12.6
x
|
-6.72
x
|
26.5
x
|
-58.5
x
|
FCF Yield
|
1.45%
|
1.61%
|
7.91%
|
-14.9%
|
3.78%
|
-1.71%
|
Price to Book
|
3.48
x
|
3.59
x
|
3.34
x
|
3.73
x
|
4.09
x
|
4.62
x
|
Nbr of stocks (in thousands)
|
243,000
|
243,000
|
243,000
|
243,000
|
243,000
|
243,000
|
Reference price
2 |
7.100
|
7.610
|
7.100
|
8.210
|
9.580
|
11.34
|
Announcement Date
|
28/03/19
|
27/03/20
|
25/03/21
|
27/01/22
|
29/03/23
|
29/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
877.6
|
870.4
|
761.8
|
669.8
|
894.2
|
925.1
|
EBITDA
1 |
33.17
|
28.88
|
48.09
|
23.33
|
27.67
|
32.81
|
EBIT
1 |
19.52
|
13.88
|
32.76
|
7.844
|
8.211
|
13.53
|
Operating Margin
|
2.22%
|
1.59%
|
4.3%
|
1.17%
|
0.92%
|
1.46%
|
Earnings before Tax (EBT)
1 |
46.51
|
32.98
|
22.83
|
24.63
|
60.74
|
54.93
|
Net income
1 |
35.23
|
21.98
|
13.67
|
21.72
|
39.95
|
39.3
|
Net margin
|
4.01%
|
2.52%
|
1.8%
|
3.24%
|
4.47%
|
4.25%
|
EPS
2 |
0.1400
|
0.0900
|
0.0600
|
0.0900
|
0.1600
|
0.1600
|
Free Cash Flow
1 |
19.94
|
19.8
|
82.8
|
-209.5
|
61.24
|
-31.77
|
FCF margin
|
2.27%
|
2.27%
|
10.87%
|
-31.28%
|
6.85%
|
-3.43%
|
FCF Conversion (EBITDA)
|
60.12%
|
68.57%
|
172.18%
|
-
|
221.3%
|
-
|
FCF Conversion (Net income)
|
56.59%
|
90.1%
|
605.51%
|
-
|
153.28%
|
-
|
Dividend per Share
2 |
0.0450
|
0.0280
|
0.0170
|
0.0270
|
0.0500
|
0.0490
|
Announcement Date
|
28/03/19
|
27/03/20
|
25/03/21
|
27/01/22
|
29/03/23
|
29/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
167
|
283
|
350
|
180
|
261
|
240
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
19.9
|
19.8
|
82.8
|
-210
|
61.2
|
-31.8
|
ROE (net income / shareholders' equity)
|
7.01%
|
4.25%
|
2.48%
|
3.07%
|
7.13%
|
6.92%
|
ROA (Net income/ Total Assets)
|
1.18%
|
0.84%
|
1.96%
|
0.47%
|
0.45%
|
0.67%
|
Assets
1 |
2,974
|
2,607
|
696
|
4,666
|
8,836
|
5,897
|
Book Value Per Share
2 |
2.040
|
2.120
|
2.120
|
2.200
|
2.340
|
2.450
|
Cash Flow per Share
2 |
0.6700
|
0.9500
|
1.100
|
0.7100
|
1.240
|
0.6500
|
Capex
1 |
1.68
|
4.55
|
6.86
|
240
|
3.89
|
7.27
|
Capex / Sales
|
0.19%
|
0.52%
|
0.9%
|
35.88%
|
0.44%
|
0.79%
|
Announcement Date
|
28/03/19
|
27/03/20
|
25/03/21
|
27/01/22
|
29/03/23
|
29/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -23.10% | 218M | | +29.50% | 78.4B | | +0.30% | 25.12B | | +14.70% | 8.62B | | +2.20% | 8.55B | | -28.87% | 6.91B | | +16.06% | 5.34B | | +1.58% | 4.17B | | -8.90% | 3.82B | | -7.62% | 3.37B |
Pharmaceuticals Wholesale
|